A light-up probe with aggregation-induced emission characteristics (AIE) for selective imaging, naked-eye detection and photodynamic killing of Gram-positive bacteria

2015 ◽  
Vol 51 (62) ◽  
pp. 12490-12493 ◽  
Author(s):  
Guangxue Feng ◽  
Youyong Yuan ◽  
Hu Fang ◽  
Ruoyu Zhang ◽  
Bengang Xing ◽  
...  

We report a multifunctional light-up probe based on AIEgens for selective recognition, naked-eye identification, and photodynamic killing of Gram-positive bacteria including vancomycin-resistant strains.

RSC Advances ◽  
2018 ◽  
Vol 8 (44) ◽  
pp. 25094-25103 ◽  
Author(s):  
Cheong Shin ◽  
Ha Neul Lee ◽  
Jea Sung Ryu ◽  
Hyun Jung Chung

A rapid, colorimetric assay based on aggregation of nanobeads functionalized with vancomycin is developed for naked-eye detection of Gram-positive bacteria.


2018 ◽  
Vol 6 (23) ◽  
pp. 3894-3903 ◽  
Author(s):  
Miaomiao Kang ◽  
Ryan T. K. Kwok ◽  
Jianguo Wang ◽  
Han Zhang ◽  
Jacky W. Y. Lam ◽  
...  

A positively charged multifunctional AIEgen was developed for selective imaging and photodynamic killing of cancer cells as well as Gram-positive bacteria.


2005 ◽  
Vol 25 (4) ◽  
pp. 313-319 ◽  
Author(s):  
William Salzer

The incidence of resistant gram-positive bacteria in nosocomial and, more recently, community-acquired infections is increasing. Staphylococci, because of their natural habitat on the skin, have always been the leading cause of peritonitis in patients receiving peritoneal dialysis (PD). These organisms have demonstrated a remarkable ability to develop resistance to antibiotics, first with penicillin, then antistaphylococcal penicillins (methicillin-resistant Staphylococcus aureus), and more recently, strains expressing resistance to vancomycin (vancomycin-intermediate and vancomycin-resistant S. aureus) have emerged. Enterococci are normal inhabitants of the gastrointestinal tract and occasionally cause PD peritonitis. In the past 15 years, vancomycin-resistant enterococci have emerged as significant pathogens in many areas. In the past 5 years, novel antibiotics that have activity on gram-positive bacteria, including vancomycin-resistant strains, have become available. The problem of resistant gram-positive bacteria in PD peritonitis, their therapy, and the role of these newer agents, quinupristin/dalfopristin, linezolid, and daptomycin, are reviewed.


2020 ◽  
Vol 56 (17) ◽  
pp. 2630-2633 ◽  
Author(s):  
Jiabao Zhuang ◽  
Hanxiao Yang ◽  
Yue Li ◽  
Bing Wang ◽  
Nan Li ◽  
...  

Efficient photosensitizers with aggregation-induced emission effects were reported to selectively stain lysosome and Gram-positive bacteria, which further triggered the ablation of cancer cells and bacteria under white light irradiation.


2020 ◽  
Author(s):  
Thibaud Rossel ◽  
Marc Creus

In the presence of bovine carbonic anhydrase(bCA) and human carbonic anhydrase (hCAII), [Cu<sub>2</sub>(HXTA-ArS)]<sup>-</sup> at physiological pH offered a synthetic receptor allowing exquisite naked-eye selective recognition of glyphosate.


2004 ◽  
Vol 48 (8) ◽  
pp. 3043-3050 ◽  
Author(s):  
Sharath S. Hegde ◽  
Noe Reyes ◽  
Tania Wiens ◽  
Nicole Vanasse ◽  
Robert Skinner ◽  
...  

ABSTRACT Telavancin (TD-6424) is a novel lipoglycopeptide that produces rapid and concentration-dependent killing of clinically relevant gram-positive organisms in vitro. The present studies evaluated the in vivo pharmacodynamics of telavancin in the mouse neutropenic thigh (MNT) and mouse subcutaneous infection (MSI) animal models. Pharmacokinetic-pharmacodynamic studies in the MNT model demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC ratio was the best predictor of efficacy. Telavancin produced dose-dependent reduction of thigh titers of several organisms, including methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA), penicillin-susceptible and -resistant strains of Streptococcus pneumoniae, and vancomycin-resistant Enterococcus faecalis. The 50% effective dose (ED50) estimates for telavancin ranged from 0.5 to 6.6 mg/kg of body weight (administered intravenously), and titers were reduced by up to 3 log10 CFU/g from pretreatment values. Against MRSA ATCC 33591, telavancin was 4- and 30-fold more potent (on an ED50 basis) than vancomycin and linezolid, respectively. Against MSSA ATCC 13709, telavancin was 16- and 40-fold more potent than vancomycin and nafcillin, respectively. Telavancin, vancomycin, and linezolid were all efficacious and more potent against MRSA ATCC 33591 in the MSI model compared to the MNT model. This deviation in potency was, however, disproportionately greater for vancomycin and linezolid than for telavancin, suggesting that activity of telavancin is less affected by the immune status. The findings of these studies collectively suggest that once-daily dosing of telavancin may provide an effective approach for the treatment of clinically relevant infections with gram-positive organisms.


2005 ◽  
pp. 2924 ◽  
Author(s):  
Jean-Luc Fillaut ◽  
Julien Andriès ◽  
Loïc Toupet ◽  
Jean-Pierre Desvergne

Sign in / Sign up

Export Citation Format

Share Document